Lansing Street Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
Lansing Street Advisors's BMY Position: Q2 2026 in Review
Lansing Street Advisors reduced its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, selling an estimated $7.06K and leaving 10,355 shares worth $597K. The position accounts for 0.13% of the portfolio, ranked #99.
Lansing Street Advisors first reported a position in BMY in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.21M in Q4 2022. 949 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Lansing Street Advisors held 10,355 shares of Bristol-Myers Squibb worth $597K as of Q2 2026.
- Lansing Street Advisors sold 123 Bristol-Myers Squibb shares in Q2 2026, an estimated $7.06K.
- Bristol-Myers Squibb made up 0.13% of Lansing Street Advisors's portfolio in Q2 2026, its #99 holding.
- Lansing Street Advisors first reported a position in Bristol-Myers Squibb in Q1 2022 and has held it in 17 quarters since.
- Lansing Street Advisors's Bristol-Myers Squibb position peaked at $2.21M in Q4 2022.
- 949 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Lansing Street Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.